Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 4/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358107 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL37117 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL7795348 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL1176710 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL1279390 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL2301401 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL20520253 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL20520255 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL20520239 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA | |
| SCHEMBL9702424 | 1.00 | CA1 (0.54) | CA1ACE2FDPSSPHK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031890-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2015-01-29 | — | — | US | claimed |
| EP-2789337-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS | Industry-Academic Cooperation Foundation Yeungnam University (KR) | 2014-10-15 | — | — | EP | claimed |
| JP-4579415-B2 | — | — | 2010-11-10 | — | — | JP | claimed |
| US-20030125573-A1 | Method of vitamin production | DCV, INC., D/B/A BIO-TECHNICAL RESOURCES | 2003-07-03 | — | — | US | claimed |
| WO-2003012170-A1 | VAPOR-PHASE CORROSION-INHIBITORS AND METHOD FOR PREPARING THE SAME | EXCOR KORROSIONSFORSCHUNG GMBH (DE) | 2003-02-13 | — | — | WO | claimed |
| EP-1095002-A1 | METHOD OF VITAMIN PRODUCTION | DCV Inc. doing business as Bio-Technical Resourses (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000001650-A1 | METHOD OF VITAMIN PRODUCTION | DCV, INC. DOING BUSINESS AS BIO-TECHNICAL RESOURCES (US) | 2000-01-13 | — | — | WO | claimed |
| WO-1999024417-A1 | ANALOGS OF VITAMIN E | MCGILL UNIVERSITY (CA) | 1999-05-20 | — | — | WO | claimed |
| CN-118355051-A | Polycarbonate resin composition | 三菱化学株式会社 | 2024-07-16 | — | — | CN | disclosed |
| CN-117916286-A | Polycarbonate resin composition | 三菱化学株式会社 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024071045-A1 | POLYCARBONATE RESIN AND MOLDED ARTICLE CONTAINING SAME | 富士フイルム株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024024943-A1 | POLYCARBONATE RESIN COMPOSITION | 三菱ケミカル株式会社 | 2024-02-01 | — | — | WO | disclosed |
| EP-3450431-B1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023149329-A1 | POLYCARBONATE RESIN COMPOSITION | 三菱ケミカル株式会社 | 2023-08-10 | — | — | WO | disclosed |
| US-4661610-A | Preparation of veratryl cyanide | BASF AKTIENGESELLSCHAFT (DE) | 1987-04-28 | — | — | US | disclosed |
| EP-0211271-A1 | Process for the preparation of veratryl cyanide | BASF Aktiengesellschaft (DE) | 1987-02-25 | — | — | EP | disclosed |
| EP-0142797-A2 | Method for the preparation of acetonitriles substituted in position 2 by an aromatic or heterocyclic substituent | BASF Aktiengesellschaft (DE) | 1985-05-29 | — | — | EP | disclosed |
| EP-0046194-B1 | PROCESS FOR THE PREPARATION OF O,O-DISUBSTITUTED BENZOIC ACIDS AND THEIR SALTS | BASF Aktiengesellschaft (DE) | 1983-10-05 | — | — | EP | disclosed |
| EP-0046194-A1 | Process for the preparation of o,o-disubstituted benzoic acids and their salts | BASF Aktiengesellschaft (DE) | 1982-02-24 | — | — | EP | disclosed |
| EP-0019158-A1 | Process for the production of m-substituted N-methylanilines | BASF Aktiengesellschaft (DE) | 1980-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125573-A1 | Method of vitamin production | TTPA, FNTA, GGPS1 | CA1 4808/4885ACE2 1300/4885FDPS 8/4885 |
| US-20150031890-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS | PGF, FLT1, VEGFA | CA1 4615/4885ACE2 1378/4885FDPS 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.